Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Lundbeck Jumps as Depression Drug Gets Praise: Copenhagen Mover

H. Lundbeck A/S rose the most in seven weeks in Copenhagen trading after JPMorgan Chase & Co. said the Nordic region’s second-largest drugmaker will revive growth with its experimental depression treatment Brintellix.

Lundbeck rose as much as 4.2 percent, the most since March 26, which made the stock today’s biggest winner in the OMX Copenhagen 20 index. The shares of the Copenhagen-based company gained 3.3 percent to 116.50 kroner at 11:24 a.m., with trading volume at 87 percent of the three-month daily average.

Lundbeck, which is losing revenue as patents on its bestselling anti-depressant Lexapro expire, said last month that Brintellix met primary and secondary endpoints in a test. The medicine will be as effective as existing antidepressants with fewer side effects, JPMorgan said. It started coverage of Lundbeck today with an overweight recommendation.

“We expect upcoming U.S. Brintellix approval to secure a return to strong growth from 2016 onwards,” James Gordon, an analyst with JPMorgan, said in a note. “We forecast peak Brintellix sales of $2.4 billion, driven by a cleaner tolerability profile.”

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.